Annual Meeting of the NCI Cohort Consortium (Abstract Submission): Submission #17

Lightning Talks Abstract
------------------------






Presenter's First Name: : Jongeun









Presenter's Last Name:: Rhee









Title (eg: professor, assistant professor, chair, etc):: Research Fellow









Degree(s): ScD, MS









Contact Email:: jongeun.rhee@nih.gov









Organization:: NCI/DCEG









Project Title:: Serum concentrations of per- and polyfluorinated substances and risk of non-Hodgkin lymphoma 









Additional Authors:
1. First Name: Jani
   Last Name: Koponen
   Degree(s): MSc
   Organization: Finnish Institute of Health and Welfare
2. First Name: Joshua
   Middle Initial: N
   Last Name: Sampson
   Degree(s): PhD, MS
   Organization: NCI/DCEG
3. First Name: Alexander
   Middle Initial: P
   Last Name: Keil
   Degree(s): PhD, MSPH
   Organization: NCI/DCEG
4. First Name: Mary
   Middle Initial: H
   Last Name: Ward
   Degree(s): PhD
   Organization: NCI/DCEG
5. First Name: Jonathan
   Middle Initial: N
   Last Name: Hofmann
   Degree(s): PhD, MPH
   Organization: NCI/DCEG
6. First Name: Wen-Yi
   Last Name: Huang
   Degree(s): PhD, MSPH
   Organization: NCI/DCEG
7. First Name: Debra
   Middle Initial: T
   Last Name: Silverman
   Degree(s): ScD, ScM
   Organization: NCI/DCEG
8. First Name: Panu
   Last Name: Rantakokko
   Degree(s): PhD
   Organization: Finnish Institute of Health and Welfare
9. First Name: Mark
   Middle Initial: P
   Last Name: Purdue
   Degree(s): PhD
   Organization: NCI/DCEG










Abstract::
Per- and polyfluoroalkyl substances (PFAS) are persistent organic pollutants detectable in the serum of most U.S. adults. Some studies of highly-exposed individuals have suggested positive associations between PFAS and non-Hodgkin lymphoma (NHL). To investigate whether associations exist at lower exposure levels, we conducted a nested case-control study investigating serum PFAS and NHL within the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. We measured pre-diagnostic serum concentrations of five PFAS among 706 cases and 706 matched controls. We estimated odds ratios (ORs) and 95% confidence intervals (CIs) for PFAS in relation to NHL, overall and for histologic subtypes [diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL), and marginal zone lymphoma (MZL)] using conditional logistic regression. We found no evidence of a positive association with NHL for any of the five PFAS. In analyses of histologic subtypes, perfluorohexane sulfonate (PFHxS) was significantly associated with DLBCL in a model adjusting for all other PFAS (OR for highest vs. lowest quintile =2.19, 95% CI=1.21, 3.95; Ptrend=0.02), but not without mutual adjustment (OR=1.37, 95% CI=0.82, 2.29; Ptrend=0.26). We also observed an inverse association between perfluorononanoate and DLBCL (mutually-adjusted OR=0.83, 95% CI=0.69, 0.99 per doubling in concentration), although the association was only apparent among those with blood drawn in 1997 or later (Pinteraction=0.0003). In conclusion, our findings from a prospective cohort study with PFAS concentrations comparable to the general population do not support an association with increased risk of NHL overall. The suggestive positive association between PFHxS and DLBCL warrants further investigation.